American Heart Journal
Volume 149, Issue 5 , Pages 846-850 , May 2005

Correlation between the TIMI risk score and high-risk angiographic findings in non–ST-elevation acute coronary syndromes: Observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial

  • Jessica L. Mega, MD

      Affiliations

    • TIMI Study Group
    • ,
  • David A. Morrow, MD, MPH

      Affiliations

    • TIMI Study Group
    • Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass
    • Corresponding Author InformationReprint requests. David A. Morrow, MD, MPH, TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115.
    • ,
  • Marc S. Sabatine, MD, MPH

      Affiliations

    • TIMI Study Group
    • Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Xue-Qiao Zhao, MD

      Affiliations

    • Department of Medicine, University of Washington School of Medicine, Seattle, Wash
    • ,
  • Steven M. Snapinn, PhD

      Affiliations

    • Merck & Co., West Point, Pa
    • ,
  • Peter M. DiBattiste, MD

      Affiliations

    • Merck & Co., West Point, Pa
    • ,
  • C. Michael Gibson, MS, MD

      Affiliations

    • TIMI Study Group
    • ,
  • Elliott M. Antman, MD

      Affiliations

    • TIMI Study Group
    • Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Eugene Braunwald, MD

      Affiliations

    • TIMI Study Group
    • Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Pierre Théroux, MD

      Affiliations

    • Montreal Heart Institute, Quebec, Canada

Received 30 January 2004 ,Accepted 11 August 2004.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The PRISM-PLUS trial was supported by Merck & Co, Inc.

PII: S0002-8703(04)00765-3

doi: 10.1016/j.ahj.2004.08.042

American Heart Journal
Volume 149, Issue 5 , Pages 846-850 , May 2005

Article Tools

* Image Usage & Resolution